Why SARS-CoV-2 was not a Baric-created vaccine candidate: A recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform using transcription regulatory networks, as invented by Baric

In RNA viruses like coronaviruses, recombination is a central driver of genetic diversity and a potential mechanism for virulence reversion in live-attenuated vaccines. Recombination frequently occurs at the transcription regulatory networks (TRN), which guide the production of subgenomic RNAs (sgRNAs) during discontinuous transcription. Ralph Baric’s laboratory pioneered a strategy to disrupt this vulnerability by reengineering the TRN elements in the viral genome.

Schematic of the rewired TRN SARS-CoV mutants. The SARS-CoV genome is depicted, with open reading frames (ORFs) indicated. The locations of mouse-adapted mutations are denoted by black triangles. The location of each characterized TRS is denoted by a red box. The specific TRS core sequences are listed underneath the genome. From Reference 2.

Baric’s approach involves replacing native TRS consensus sequences with synthetic, noncanonical variants. These modified TRSs are still functional for viral transcription but incompatible with the wild-type TRS machinery. As a result, any recombination event involving a wild-type virus and the engineered genome would fail to yield a viable recombinant, due to misaligned or nonfunctional TRS pairing.

This effectively "locks" the vaccine genome against homologous recombination with circulating coronaviruses, a significant concern in deploying live-attenuated platforms. By decoupling compatibility at critical recombination hotspots, these engineered viruses maintain immunogenicity while significantly reducing the risk of generating chimeric pathogens. This synthetic attenuation strategy represents a sophisticated tool in rational vaccine design—fusing molecular virology with biosecurity.

Conclusion: If SARS-CoV-2 was made by Baric and was intended to be a vaccine it would have had a bespoke TRN. In fact, SARS-CoV-2 has a wildtype TRN.